drugset / Trial / NCT05862285
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this extension study is to provide continued treatment with Roche investigational medicinal product (IMP\[s\]) monotherapy or Roche IMP(s) combined with other agent(s) or comparator agent(s) for eligible participants with cancer who are still on study treatment at the time of roll-over from the parent study and who do not have access to the study treatment locally.
Timeline
- Start
- 2023-06-01
- Primary completion
- 2033-03-01
- Completion
- 2033-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | — | Intravenous |
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | Divarasib | Small molecule | — | — |
| Subject | Entrectinib | Small molecule | — | — |
| Subject | Inavolisib | Small molecule | — | — |
| Subject | Ipatasertib | Small molecule | — | — |
| Subject | Tiragolumab | Monoclonal antibody | — | Intravenous |